42 results about "Aberrant tissue" patented technology

A computer assisted, minimally invasive method and apparatus for surgically removing abnormal tissue from a patient, for example, from a breast, are disclosed. The method involves imaging of the breast to locate the abnormal tissue, and determining a volume encapsulating the abnormal tissue and including a margin of healthy tissue. Based on the volume, a sequence of movements of a surgical instrument for tissue removal device is planned, so as to predictably excise the desired volume of tissue.

An ablation catheter system and method of use is provided to endoscopically access portions of the human esophagus experiencing undesired growth of columnar epithelium. The ablation catheter system and method includes controlled depth of ablation features and use of either radio frequency spectrum, non-ionizing ultraviolet radiation, warm fluid or microwave radiation, which may also be accompanied by improved sensitizer agents.

A system provides heart ablation unit control. The system includes an input processor for acquiring electrophysiological signal data from multiple tissue locations of a heart and data indicating tissue thickness at the multiple tissue locations. A signal processor processes the acquired electrophysiological signal data to identify location of particular tissue sites of the multiple tissue locations exhibiting electrical abnormality in the acquired electrophysiological signal data and determines an area of abnormal tissue associated with individual sites of the particular sites. An ablation controller automatically determines ablation pulse characteristics for use in ablating cardiac tissue at an individual site of the particular tissue sites in response to the acquired data indicating the thickness of tissue and determined area of abnormality of the individual site.

Embodiments receive images of a body area of a patient; identify abnormal tissue in the image; generate a data set with the abnormal tissue masked out; deform a model template in space so that features in the deformed model template line up with corresponding features in the data set; place data representing the abnormal tissue back into the deformed model template; generate a model of electrical properties of tissues in the body area based on the deformed and modified model template; and determine an electrode placement layout that maximizes field strength in the abnormal tissue by using the model of electrical properties to simulate electromagnetic field distributions in the body area caused by simulated electrodes placed respective to the body area. The layout can then be used as a guide for placing electrodes respective to the body area of the patient to apply TTFields to the body area.

Light is administered during photodynamic therapy (PDT) for an extended period of time at a plurality of sites distributed within the abnormal tissue of a tumor. A clinical study has shown that a substantially greater volume of abnormal tissue in a tumor is destroyed by the extended administration of light therapy from a plurality of probes than would have been expected based upon the teaching of the prior art. In this process, a plurality of light emitting optical fibers or probes are deployed in a spaced-apart array. After a photoreactive agent is absorbed by the abnormal tissue, the light therapy is administered for at least three hours. The greater volume of necrosis in the tumor is achieved due to one or more concomitant effects, including: the inflammation of damaged abnormal tissue and resultant immunological response of the patient's body; the diffusion and circulation of activated photoreactive agent outside the expected fluence zone, which is believed to destroy the abnormal tissue; a retrograde thrombosis or vascular occlusion outside of the expected fluence zone; and, the collapse of the vascular system that provides oxygenated blood to portions of the tumor outside the expected fluence zone. In addition, is possible that molecular oxygen diffusing and circulating into the expected fluence zone is converted to singlet oxygen during the extended light therapy, causing a gradient of hypoxia and anoxia that destroys the abnormal tissue outside the expected fluence zone.

A computer assisted, minimally invasive method and apparatus for surgically removing abnormal tissue from a patient, for example, from a breast, are disclosed. The method involves imaging of the breast to locate the abnormal tissue, and determining a volume encapsulating the abnormal tissue and including a margin of healthy tissue. Based on the volume, a sequence of movements of a surgical instrument for tissue removal device is planned, so as to predictably excise the desired volume of tissue.

A method is provided for determining contact of a sensor with a patient's tissue. The method comprises comparing the intensity of detected light at a first wavelength to a threshold, wherein the first wavelength is not used to determine a physiological characteristic of the patient, and determining if the sensor is in contact with the patient's tissue based on the comparison. In addition, a method is provided for determining the amount of light shunting during operation of the sensor. The method comprises comparing the intensity of detected light at a first wavelength to a threshold, wherein the first wavelength is not used to determine a physiological characteristic of the patient, and determining the amount of light shunting based on the comparison.

The present invention, in one aspect, relates to a method for examining a target for tumors or lesions using what is referred to as “Early Increase in microvascular Blood Supply” (EIBS) that exists in tissues that are close to, but are not themselves, the abnormal tissue and in tissues that precede the development of such lesions or tumors. While the abnormal tissue can be a lesion or tumor, the abnormal tissue can also be tissue that precedes formation of a lesion or tumor, such as a precancerous adenoma, aberrant crypt foci, tissues that precede the development of dysplastic lesions that themselves do not yet exhibit dysplastic phenotype, and tissues in the vicinity of these lesions or pre-dysplastic tissues.

Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and / or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and / or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.

A method is provided for determining contact of a sensor with a patient's tissue. The method comprises comparing the intensity of detected light at a first wavelength to a threshold, wherein the first wavelength is not used to determine a physiological characteristic of the patient, and determining if the sensor is in contact with the patient's tissue based on the comparison. In addition, a method is provided for determining the amount of light shunting during operation of the sensor. The method comprises comparing the intensity of detected light at a first wavelength to a threshold, wherein the first wavelength is not used to determine a physiological characteristic of the patient, and determining the amount of light shunting based on the comparison.

An optical system and apparatus for the diagnosis of a biological sample is disclosed. An embodiment of the apparatus includes an optical probe, a probe head distally connectable to the optical probe, the optical probe further comprising at least one optical element for applying an electromagnetic radiation of a first wavelength to the biological sample, and one or more collection elements positioned proximate the at least one optical element; and an analyzer for analyzing a signal received from the biological sample by the one or more collection elements.

A method for detecting abnormal tissue in a region of healthy tissue, comprising:a) making a first measurement of ultrasound backscattered from the region;b) heating the region, at least after the first measurement;c) making one or more additional measurements of ultrasound backscattered from the region after some or all of the heating; andd) analyzing the measurements to detect the abnormal tissue by finding differences in changes, caused by the heating, of one or more characteristics of ultrasound backscattering, between the abnormal tissue and the healthy tissue.

A method and system are provided for determining a condition of a selected region of tissue to facilitate the location of surgical resection margins. Electropotential and impedance are measured at one or more locations in an area of the body where tissue is to be removed. An agent may be introduced into the region of tissue to enhance electrophysiological characteristics of that tissue. The condition of the tissue is measured by electropotential and impedance profile. Differences in the profile are used to determine the borders between normal and abnormal tissue so as to facilitate what tissue to resect. Methods and apparatus are also disclosed to determine the efficacy of various therapies.

An apparatus for the diagnosis of a biological sample is disclosed. An embodiments of the apparatus includes a probe, a probe head distally connectable to the probe, the probe head further comprising a plurality of electrode elements thereby forming an electrode array where each electrode element is variably actuatable to apply an electrical signal to the biological sample; an RF signal source for applying the electrical signal to the electrode array; an electrode selector adapted and configured to switch the electrical signal from the RF signal source between the plurality of electrode elements; and a detection circuit for analyzing a dielectric property received from the biological sample. Methods and kits for diagnosing a biological sample are also disclosed.

An apparatus for the diagnosis of a biological sample is disclosed. An embodiments of the apparatus includes a probe, a probe head distally connectable to the probe, the probe head further comprising a plurality of electrode elements thereby forming an electrode array where each electrode element is variably actuatable to apply an electrical signal to the biological sample; an RF signal source for applying the electrical signal to the electrode array; an electrode selector adapted and configured to switch the electrical signal from the RF signal source between the plurality of electrode elements; and a detection circuit for analyzing a dielectric property received from the biological sample. Methods and kits for diagnosing a biological sample are also disclosed.

Methods and systems related to detecting disease, such as oral cancer, in a patient, using a viewing scope to investigate a patient's tissues. The systems and methods excite and detect fluorescence from the tissue. The fluorescence can then be evaluated, and the possibility of certain diseases such as cancer can be determined. The devices include an ambient light management system (ALMS, often referred to as a “vestibular device”) that manages background light in the health practitioner's office. This device can be used with scope systems for fluorescence based detection of abnormal tissue.

A method and system for classifying tissue suspected of being abnormal as being malignant or benign. The method includes generating a set of selection features, performing statistical applications to generate additional selection features, generating a feature vector for the abnormal tissue, feeding the feature vector into a neural network, and obtaining a result from the neural network as to whether the abnormal tissue is malignant or benign. The method and system may be used for determining the presence of breast cancer.

An optical system and apparatus for the diagnosis of a biological sample is disclosed. An embodiment of the apparatus includes an optical probe, a probe head distally connectable to the optical probe, the optical probe further comprising at least one optical clement for applying an electromagnetic radiation of a first wavelength to the biological sample, and one or more collection elements positioned proximate the at least one optical element; and an analyzer for analyzing a signal received from the biological sample by the one or more collection elements.

The present invention, in one aspect, relates to a method of and apparatus for examining a target for tumors or lesions using what is referred to as ''Early Increase in microvascular Blood Supply'' (EIBS) that exists in tissues that are close to, but are not themselves, the abnormal tissue and in tissues that precede the development of such lesions or tumors. While the abnormal tissue can be a lesion or tumor, the abnofmal tissue can also be tissue that precedes formation of a lesion or tumor, such as a precancerous adenoma, aberrant crypt foci, tissues that precede the development of dysplastic lesions that themselves do not yet exhibit dysplastic phenotype, and tissues in the vicinity of these lesions or pre-dysplastic tissues.

Methods and systems related to detecting disease, such as oral cancer, in a patient, using a viewing scope to investigate a patient's tissues. The systems and methods excite and detect fluorescence from the tissue. The fluorescence can then be evaluated, and the possibility of certain diseases such as cancer can be determined. The devices include an ambient light management system ALMS, often referred to as a vestibular device that manages background light in the health practitioner's office. This device can be used with scope systems for fluorescence based detection of abnormal tissue.

The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.

In a light-directed method of identifying abnormal mucosal tissue, any suspect sites revealed by a light that selectively aids in visualizing abnormal tissue are marked with a dye facilitate further evaluation of the suspect tissue.

A device is described for measuring electrical characteristics of biological tissues with plurality of electrodes and a processor controlling the stimulation and measurement in order to detect the presence of abnormal tissue masses in organs. Examples of suitable organs are the breast, skin, oral cavity, lung, liver, colon, rectum, cervix, and prostate and determine probability of tumors containing malignant cancer cells being present in tissue. The approach can also be applied to biopsied tissue samples. The device has the capability of providing the location of the abnormality. The method for measuring electrical characteristics includes placing electrodes and applying a voltage waveform in conjunction with a current detector. A mathematical analysis method is then applied to the collected data, which computes spectrum of frequencies and correlates magnitudes and phases with given algebraic conditions to determine mass presence and type.

The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.

The visibility of abnormal tissue under light having wavelength peaks which selectively identify abnormal tissue is enhanced in the presence of normal ambient light by viewing the tissue through lens which transmit the wavelength peaks but block transmission of other wavelengths.

A device is described for measuring electrical characteristics of biological tissues with plurality of electrodes and a processor controlling the stimulation and measurement in order to detect the presence of abnormal tissue masses in organs. Examples of suitable organs are the breast, skin, oral cavity, lung, liver, colon, rectum, cervix, and prostate and determine probability of tumors containing malignant cancer cells being present in tissue. The approach can also be applied to biopsied tissue samples. The device has the capability of providing the location of the abnormality. The method for measuring electrical characteristics includes placing electrodes and applying a voltage waveform in conjunction with a current detector. A mathematical analysis method is then applied to the collected data, which computes spectrum of frequencies and correlates magnitudes and phases with given algebraic conditions to determine mass presence and type.

The invention discloses a paraffin-embedded tissue sample processing method and a kit for tumor prognosis evaluation. The method comprises the following steps: obtaining a cell nucleus monolayer from a paraffin-embedded tumor tissue sample, dyeing the cell nucleus by using a dyeing reagent, and collecting an image by using a digital pathological scanning analysis system. The content of cell DNA in the abnormal tissue is detected through image analysis of the gray scale and the IOD value of the cell nucleus, and the DNA ploidy is reflected; through image analysis of cell nucleus textures, chromatin structures are quantified, and the structures comprehensively reflect gene changes and epigenetics changes. According to the method, the combined quantitative analysis of two prognosis risk factors is realized on the paraffin-embedded tissue sample through one-time sampling and one-time processing flow by utilizing a digital pathological scanning analysis system, and the analysis result can be used for prognosis evaluation of a patient, so that the efficiency and the accuracy of evaluation work are greatly improved, and reasonable medication is guided.

The invention discloses a reagent fixed-point release method based on ultrasonic microbubble radiography, which relates to the technical field of image processing, and comprises the following steps: performing tissue injection containing specific reagent microbubbles according to the type of abnormal tissues; the supermolecule image of the whole tissue is obtained through high-frequency ultrasonic waves; according to the supramolecular imaging, using the convolutional neural network trained by the image corresponding to the abnormal tissue to perform identification determination and region extraction of the abnormal tissue; focusing of low-frequency ultrasonic waves is carried out according to the area where the abnormal tissue is located; microbubbles in the area where the abnormal tissue is located are burst through the focused low-frequency ultrasonic waves, and specific reagents carried by the microbubbles are released. According to the method, after the supramolecular image is obtained through the high-frequency ultrasonic waves, the edge of the abnormal tissue is defined through the convolutional neural network model, and the ultrasonic waves are changed into low frequency to perform fixed-point microbubble burst control, so that abnormal tissue structure screening and repairing are combined, and the variation degree of the abnormal tissue can be judged.